Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 16 Genitourinary 8 Gastrointestinal 8 Breast 5 Sarcoma 3 Tumor-Agnostic 2 Thoracic 2 Other hematologic neoplasm 2 NET 2 Myeloid 2 Lymphoid 2 Head & Neck 2 Endocrine 2 CNS 2 Plasma cell 1

Conditions

Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1

Interventions

Dexamethasone 47 Lenalidomide 31 daratumumab 24 Bortezomib 23 pomalidomide 19 carfilzomib 15 Specimen Handling 15 Cyclophosphamide 15 Calcium Dobesilate 15 Biopsy 15 Magnetic Resonance Spectroscopy 11 talquetamab 9 isatuximab 9 Melphalan 9 iberdomide 8 dexamethasone acetate 8 dexamethasone 21-phosphate 8 auricularum 8 fludarabine 7 belantamab mafodotin 7 selinexor 5 X-Rays 5 tocilizumab 4 fludarabine phosphate 4 elotuzumab 4 Nuclear Medicine Department, Hospital 4 trametinib 3 dabrafenib 3 Whole-Body Irradiation 3 Thalidomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

olaparib × Plasma cell × 30 days × Clear all

NCT02693535 2026-05-29

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡